Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer

Life Sci
23 July 1984
https://pubmed.ncbi.nlm.nih.gov/6087062/

Naltrexone modulates tumor response in mice with neuroblastoma

Science
12 August 1983
https://pubmed.ncbi.nlm.nih.gov/6867737/

Opioid antagonists inhibit the growth of metastatic murine neuroblastoma

Cancer Lett
November 1983
https://pubmed.ncbi.nlm.nih.gov/6640516/

Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors

Front Immunol
11 July 2017
https://pubmed.ncbi.nlm.nih.gov/28744288/

The Use of Naltrexone in Low Doses Beyond the Approved Indication [Internet]

Report from Norwegian Knowledge Centre for the Health Services
April 2015
https://pubmed.ncbi.nlm.nih.gov/28510411/

Low dose naltrexone: Harnessing the body's own chemistry to treat human ovarian cancer

Science Daily
13 July 2011
https://www.sciencedaily.com/releases/2011/07/110712143012.htm

Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy

Int Immunopharmacol
August 2018
https://pubmed.ncbi.nlm.nih.gov/29885638/

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care

Cochrane Database Syst Rev
05 June 2018
https://www.ncbi.nlm.nih.gov/pubmed/29869799

Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion

Cureus
10 July 2018
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126779/

Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin

Exp Biol Med (Maywood)
July 2011
https://pubmed.ncbi.nlm.nih.gov/21685240/